Empreendimentos Pague Menos S.A (PGMN3)
Sao Paulo Exchange · Brazil · prices in BRL · close of 16 Oct 2026
Key indicators
| Last close | BRL 5.130 |
|---|---|
| 52-week range | 3.090 – 7.620 |
| Return, 1 month / 3 months | +34.6% / +49.1% |
| Return, 1 year / 3 years | +53.3% / +118.2% |
| Trend | Uptrend |
| RSI (14) | 66 |
| Volatility (1 year) | 53.5% |
| Worst drawdown (1 year) | -58.5% |
| Average daily value traded | 29.60M BRL |
| Dividend yield | 5.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Empreendimentos Pague Menos is a Brazilian pharmacy chain that runs drugstores under the Pague Menos banner. The company sells prescription and over-the-counter medicines, health and beauty products, personal care items and household goods through its stores, serving everyday consumers across Brazil. It is based in Fortaleza, in the state of Ceará, and its stores are typically located in shopping areas and neighbourhoods where customers shop for pharmacy and convenience products.
Empreendimentos Pague Menos S.A trades under the code PGMN3 on the Sao Paulo Exchange in Brazil, with its price quoted in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Empreendimentos Pague Menos S.A (PGMN3) trades on the Sao Paulo Exchange in Brazil. It last closed at BRL 5.130 on 16 October 2026.
Its price-based Market X-Ray is 46 out of 100 (a weak price profile), ranking 878 of 1,454 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 53.3% and over the last three months it rose 49.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Sao Paulo Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 30 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 4.3% | ||
| From 52-week high | -32.0% | ||
| Momentum | 63 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 49.1% | ||
| 6-month return | -9.5% | ||
| 12-month return, skipping the last month | 13.8% | ||
| Stability (higher is calmer) | 22 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 53.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -58.5% | ||
| Liquidity | 93 · Strong | Trades actively. | |
| Average daily value traded | 29.60M BRL | ||
| Zero-volume days | 0.0% | ||
| Income | 38 · Weak | Dividend is small or irregular. | |
| Dividend yield | 5.0% | ||
| Years with dividends | 3 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −1.9% |
|---|---|
| 1 month | +34.6% |
| 3 months | +49.1% |
| 6 months | −9.5% |
| 1 year | +53.3% |
| 3 years | +118.2% |
| 5 years | – |
Signals
| 50-day / 200-day average | 3.823 / 4.920 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.289 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 23 Dec 2025 | BRL 0.2577 |
| 20 Jan 2025 | BRL 0.2529 |
| 26 Jan 2024 | BRL 0.2958 |
| 27 Jan 2023 | BRL 0.1860 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Sao Paulo Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.